Literature DB >> 7979290

Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.

K D Moody1, R L Adams, S W Barthold.   

Abstract

Although antimicrobial agents are effective therapy for early Lyme disease, optimal treatment schedules have not been conclusively established. The efficacy of various dosages of eight antibiotics used for borreliosis treatment was evaluated for C3H/HeNCrIBR mice, which reproducibly develop persistent infection, arthritis, and carditis when inoculated with Borrelia burgdorferi. Amoxicillin-clavulanic acid, ceftriaxone, and high-dose penicillin G effectively eliminated infection and disease. Oxytetracycline, doxycycline, chloramphenicol, erythromycin, and azithromycin failed to cure infected mice. There was a correlation between peak serum antibiotic concentrations in mice, as determined by agar well diffusion bioassays, and therapeutic levels in humans. When experimentally inoculated mice were treated at 1 week postinfection with ceftriaxone (16 mg/kg of body weight twice daily for 5 days) and monitored for up to 90 days, all treated mice were free of spirochetes and had no gross or histologic lesions. This antibiotic regimen at days 7 to 11 postinoculation eliminated the spirochetes so that there were no relapses during the 90-day observation period. For experimentally inoculated mice treated with ceftriaxone at 7 or 14 days postinfection, arthritis, carditis, and infection were eliminated. When treatment began at 30 and 90 days after inoculation, infection and active cardiac and arthritic lesions were eradicated; however, residual mild synovitis and vasculitis persisted in some mice. In comparison with inoculated, untreated mice, ceftriaxone therapy at 7, 14, 30, and 90 days postinfection abrogated the development of antibody titers against B. burgdorferi. Having the potential to determine the presence of the spirochete through culture and histologic lesions makes the B. burgdorferi-inoculated C3H mouse model a valuable adjunct in evaluating chemotherapeutic options for Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979290      PMCID: PMC284594          DOI: 10.1128/AAC.38.7.1567

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.

Authors:  K Weber; V Preac-Mursic; U Neubert; R Thurmayr; P Herzer; B Wilske; G Schierz; W Marget
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

2.  Experimental Lyme arthritis in rats infected with Borrelia burgdorferi.

Authors:  S W Barthold; K D Moody; G A Terwilliger; P H Duray; R O Jacoby; A C Steere
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

3.  Failure of tetracycline therapy in early Lyme disease.

Authors:  R J Dattwyler; J J Halperin
Journal:  Arthritis Rheum       Date:  1987-04

4.  Treatment of erythema chronicum migrans of Lyme disease.

Authors:  B W Berger
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Reinfection with Borrelia burgdorferi.

Authors:  H W Pfister; U Neubert; B Wilske; V Preac-Mursic; K M Einhäupl; G D Borasio
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

6.  New chemotherapeutic approaches in the treatment of Lyme borreliosis.

Authors:  B J Luft; D J Volkman; J J Halperin; R J Dattwyler
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

7.  In vitro and in vivo susceptibility of Borrelia burgdorferi.

Authors:  V P Mursic; B Wilske; G Schierz; M Holmburger; E Süss
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

8.  European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

Authors:  V Preac-Mursic; B Wilske; G Schierz
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1986-12

9.  Lyme meningoencephalitis: report of a severe, penicillin-resistant case.

Authors:  M N Diringer; J J Halperin; R J Dattwyler
Journal:  Arthritis Rheum       Date:  1987-06

10.  Isolation and cultivation of Lyme disease spirochetes.

Authors:  A G Barbour
Journal:  Yale J Biol Med       Date:  1984 Jul-Aug
View more
  21 in total

1.  Getting under the birds' skin: tissue tropism of Borrelia burgdorferi s.l. in naturally and experimentally infected avian hosts.

Authors:  Ana Cláudia Norte; Isabel Lopes de Carvalho; Maria Sofia Núncio; Pedro Miguel Araújo; Erik Matthysen; Jaime Albino Ramos; Hein Sprong; Dieter Heylen
Journal:  Microb Ecol       Date:  2019-10-15       Impact factor: 4.552

2.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Specificity of infection-induced immunity among Borrelia burgdorferi sensu lato species.

Authors:  S W Barthold
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

Authors:  M Karlsson; S Hammers; I Nilsson-Ehle; A S Malmborg; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.

Authors:  E S Shang; C I Champion; X Y Wu; J T Skare; D R Blanco; J N Miller; M A Lovett
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

7.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

8.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 9.  Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

10.  Characterization of Borrelia burgdorferi aggregates.

Authors:  Siddharth Y Srivastava; Aravinda M de Silva
Journal:  Vector Borne Zoonotic Dis       Date:  2009-06       Impact factor: 2.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.